Cargando…
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients
Host-directed-therapy strategies are warranted to fight tuberculosis. Here we assess the safety and immunogenicity of adjunctive vaccination with the H56:IC31 candidate and cyclooxygenase-2-inhibitor treatment (etoricoxib) in pulmonary and extra-pulmonary tuberculosis patients in a randomized open-l...
Autores principales: | Jenum, Synne, Tonby, Kristian, Rueegg, Corina S., Rühwald, Morten, Kristiansen, Max P., Bang, Peter, Olsen, Inge Christoffer, Sellæg, Kjersti, Røstad, Kjerstin, Mustafa, Tehmina, Taskén, Kjetil, Kvale, Dag, Mortensen, Rasmus, Dyrhol-Riise, Anne Ma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608791/ https://www.ncbi.nlm.nih.gov/pubmed/34811370 http://dx.doi.org/10.1038/s41467-021-27029-6 |
Ejemplares similares
-
Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients
por: Jøntvedt Jørgensen, Marthe, et al.
Publicado: (2021) -
Monocytic myeloid‐derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase‐2 inhibitors
por: Jøntvedt Jørgensen, Marthe, et al.
Publicado: (2020) -
Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice
por: Mortensen, Rasmus, et al.
Publicado: (2019) -
Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors
por: Lieske, Nora V., et al.
Publicado: (2015) -
IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection
por: Tonby, Kristian, et al.
Publicado: (2015)